228 related articles for article (PubMed ID: 34305527)
1. Glucagon-Like Peptide-1 Receptor Agonist Ameliorates 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Neurotoxicity Through Enhancing Mitophagy Flux and Reducing α-Synuclein and Oxidative Stress.
Lin TK; Lin KJ; Lin HY; Lin KL; Lan MY; Wang PW; Wang TJ; Wang FS; Tsai PC; Liou CW; Chuang JH
Front Mol Neurosci; 2021; 14():697440. PubMed ID: 34305527
[TBL] [Abstract][Full Text] [Related]
2. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
[TBL] [Abstract][Full Text] [Related]
3. Cholecystokinin and glucagon-like peptide-1 analogues regulate intestinal tight junction, inflammation, dopaminergic neurons and α-synuclein accumulation in the colon of two Parkinson's disease mouse models.
Su Y; Liu N; Zhang Z; Li H; Ma J; Yuan Y; Shi M; Liu J; Zhao Z; Zhang Z; Holscher C
Eur J Pharmacol; 2022 Jul; 926():175029. PubMed ID: 35584709
[TBL] [Abstract][Full Text] [Related]
4. Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson's Disease.
Zhang L; Zhang L; Li L; Hölscher C
J Parkinsons Dis; 2019; 9(1):157-171. PubMed ID: 30741689
[TBL] [Abstract][Full Text] [Related]
5. A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease.
Yuan Z; Li D; Feng P; Xue G; Ji C; Li G; Hölscher C
Eur J Pharmacol; 2017 Oct; 812():82-90. PubMed ID: 28666800
[TBL] [Abstract][Full Text] [Related]
6. Liraglutide Regulates Mitochondrial Quality Control System Through PGC-1α in a Mouse Model of Parkinson's Disease.
Wu P; Dong Y; Chen J; Guan T; Cao B; Zhang Y; Qi Y; Guan Z; Wang Y
Neurotox Res; 2022 Feb; 40(1):286-297. PubMed ID: 35043376
[TBL] [Abstract][Full Text] [Related]
7. The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson's Disease.
Zhang L; Zhang L; Li Y; Li L; Melchiorsen JU; Rosenkilde M; Hölscher C
J Parkinsons Dis; 2020; 10(2):523-542. PubMed ID: 31958096
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model.
Zhang L; Zhang L; Li L; Hölscher C
Neuropeptides; 2018 Oct; 71():70-80. PubMed ID: 30017231
[TBL] [Abstract][Full Text] [Related]
9. Mulberry fruit ameliorates Parkinson's-disease-related pathology by reducing α-synuclein and ubiquitin levels in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model.
Gu PS; Moon M; Choi JG; Oh MS
J Nutr Biochem; 2017 Jan; 39():15-21. PubMed ID: 27741433
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective effect of anodal transcranial direct current stimulation on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity in mice through modulating mitochondrial dynamics.
Lee SB; Youn J; Jang W; Yang HO
Neurochem Int; 2019 Oct; 129():104491. PubMed ID: 31229553
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Liu W; Jalewa J; Sharma M; Li G; Li L; Hölscher C
Neuroscience; 2015 Sep; 303():42-50. PubMed ID: 26141845
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of natural resistance-associated macrophage protein-1 (Nramp1) is associated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)/1-methyl-4-phenylpyridinium (MPP
Wu KC; Liou HH; Lee CY; Lin CJ
Neuropathol Appl Neurobiol; 2019 Feb; 45(2):157-173. PubMed ID: 29679389
[TBL] [Abstract][Full Text] [Related]
13. α-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism.
Yun SP; Kim D; Kim S; Kim S; Karuppagounder SS; Kwon SH; Lee S; Kam TI; Lee S; Ham S; Park JH; Dawson VL; Dawson TM; Lee Y; Ko HS
Mol Neurodegener; 2018 Jan; 13(1):1. PubMed ID: 29310663
[TBL] [Abstract][Full Text] [Related]
14. The GLP-1/GIP dual-receptor agonist DA5-CH inhibits the NF-κB inflammatory pathway in the MPTP mouse model of Parkinson's disease more effectively than the GLP-1 single-receptor agonist NLY01.
Lv M; Xue G; Cheng H; Meng P; Lian X; Hölscher C; Li D
Brain Behav; 2021 Aug; 11(8):e2231. PubMed ID: 34125470
[TBL] [Abstract][Full Text] [Related]
15. Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease.
Feng P; Zhang X; Li D; Ji C; Yuan Z; Wang R; Xue G; Li G; Hölscher C
Neuropharmacology; 2018 May; 133():385-394. PubMed ID: 29462693
[TBL] [Abstract][Full Text] [Related]
16. 7,8-dihydroxyflavone Ameliorates Motor Deficits Via Suppressing α-synuclein Expression and Oxidative Stress in the MPTP-induced Mouse Model of Parkinson's Disease.
Li XH; Dai CF; Chen L; Zhou WT; Han HL; Dong ZF
CNS Neurosci Ther; 2016 Jul; 22(7):617-24. PubMed ID: 27079181
[TBL] [Abstract][Full Text] [Related]
17. Lutein protects dopaminergic neurons against MPTP-induced apoptotic death and motor dysfunction by ameliorating mitochondrial disruption and oxidative stress.
Nataraj J; Manivasagam T; Thenmozhi AJ; Essa MM
Nutr Neurosci; 2016 Jul; 19(6):237-46. PubMed ID: 25730317
[TBL] [Abstract][Full Text] [Related]
18. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP.
Vila M; Vukosavic S; Jackson-Lewis V; Neystat M; Jakowec M; Przedborski S
J Neurochem; 2000 Feb; 74(2):721-9. PubMed ID: 10646524
[TBL] [Abstract][Full Text] [Related]
19. Ginsenoside Rg1 attenuates motor impairment and neuroinflammation in the MPTP-probenecid-induced parkinsonism mouse model by targeting α-synuclein abnormalities in the substantia nigra.
Heng Y; Zhang QS; Mu Z; Hu JF; Yuan YH; Chen NH
Toxicol Lett; 2016 Jan; 243():7-21. PubMed ID: 26723869
[TBL] [Abstract][Full Text] [Related]
20. A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF.
Ji C; Xue GF; Lijun C; Feng P; Li D; Li L; Li G; Hölscher C
Brain Res; 2016 Mar; 1634():1-11. PubMed ID: 26453833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
